THBS3 Functions as a Novel Biomarker for Prognosis and Immunotherapeutic Response in Colorectal Cancer: An Integrative Analysis and Validation of the Thrombospondin Gene Family | Synapse
March 3, 2026Open Access
THBS3 Functions as a Novel Biomarker for Prognosis and Immunotherapeutic Response in Colorectal Cancer: An Integrative Analysis and Validation of the Thrombospondin Gene Family
Key Points
THBS3 acts as a novel biomarker for prognosis in colorectal cancer, enhancing predictive capabilities for patient outcomes.
Key evidence pointed to THBS3's significant role in therapeutic targeting and progression of CRC, with implications for treatment strategies.
Integrative analysis highlighted the relevance of the thrombospondin gene family in understanding CRC mechanisms and potential interventions.
The findings support the need for additional studies to explore the clinical utility of THBS3 in immunotherapy for colorectal cancer.
Abstract
THBS3 facilitates the progression of CRC and may serve as a novel prognostic biomarker and therapeutic target.